Drug Shortage Report for MABCAMPATH
Report ID | 207255 |
Drug Identification Number | 02290960 |
Brand name | MABCAMPATH |
Common or Proper name | Alemtuzumab |
Company Name | SANOFI-AVENTIS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | ALEMTUZUMAB |
Strength(s) | 30MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 1 ml vial |
ATC code | L04AA |
ATC description | IMMUNOSUPPRESSANTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2023-10-18 |
Estimated end date | 2023-12-25 |
Actual end date | 2023-12-18 |
Shortage status | Resolved |
Updated date | 2023-12-19 |
Company comments | Allocation has been initiated and may continue through 2023 to mitigate patient impact. |
Health Canada comments | |
Tier 3 Status | No |
Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2023-12-19 | English | Compare |
v8 | 2023-12-18 | French | Compare |
v7 | 2023-12-18 | English | Compare |
v6 | 2023-10-19 | French | Compare |
v5 | 2023-10-19 | English | Compare |
v4 | 2023-10-18 | French | Compare |
v3 | 2023-10-18 | English | Compare |
v2 | 2023-10-18 | French | Compare |
v1 | 2023-10-18 | English | Compare |
Showing 1 to 9 of 9